Colonoscopy Still Beats New Blood Tests at Spotting Colon Cancer
By Dennis Thompson HealthDay Reporter
TUESDAY, Oct. 29, 2024 -- Middle-aged folks facing a colon cancer screening now have a blood test they can choose over a standard colonoscopy.
However, the blood test isn't as effective as colonoscopy at detecting and preventing colon cancer, a new review finds.
About two and a half times more colon cancer deaths can be expected to occur in people taking the blood test every three years as recommended, compared to those who undergo colonoscopy once a decade.
Colon cancer death rates will increase if too many people choose the blood test over either colonoscopy or stool-based tests, researchers predicted.
“The first generation of blood tests are a really exciting development in the colorectal cancer screening paradigm,” said lead researcher Dr. Uri Ladabaum, a professor of gastroenterology with Stanford Medicine. “But for now, if you’re willing and able to do a colonoscopy or stool-based test, don’t switch to a blood test.”
The U.S. Food and Drug Administration in July approved the first blood test for screening colon cancer in people at average risk of the disease.
The FDA based its approval on a clinical trial involving nearly 8,000 people, which found that the test detected colon cancer in more than 83% of people with a colorectal tumor.
However, the test only was able to detect precancerous colon polyps in about 13% of people.
Colonoscopy is not an easy procedure. People must take powerful laxatives ahead of time to completely empty their bowels, and are put under sedation while doctors use a thin tube to examine the inside of the entire colon.
However, colonoscopy makes colon cancer one of the only fully preventable cancers, because doctors can remove any precancerous polyps they come across during the examination.
“This makes colonoscopy a unique cancer screening method because you also have the possibility of cancer prevention,” Ladabaum said. “Despite that, there are many people who are not getting screened at all, or who are not getting screened as often as they should.”
Patients who get a positive result from a fecal or blood test are urged to undergo colonoscopy, to double-check whether they have either cancer or polyps.
For the study, researchers pooled together data on six commercially available or in-development blood- and stool-based screening tests, as well as on gold-standard colonoscopy.
Using this data, they estimated the relative rate of colon cancer cases and deaths among people who used each screening approach.
The estimated case and death rate for every 100,000 people who choose:
Colonoscopy -- 1,543 cases and 672 deaths
Stool tests -- about 2,200 to 2,500 cases and 904 to 1,025 deaths
Blood tests -- about 4,300 cases and 1,600 deaths
No screening -- 7,500 cases and 3,600 deaths
Researchers also found that colonoscopies and stool tests are more cost-effective than blood tests.
The study was published Oct. 28 in the Annals of Internal Medicine.
“The blood tests are certainly much better than nothing, but you’ll worsen the population outcomes and raise health care costs if you see people switching from colonoscopies to first-generation blood tests,” Ladabaum said in a Stanford Medicine news release.
The best-case scenario will be if most people continue to use colonoscopy or fecal tests, and resort to a blood test only if they find those two options so repellant they would otherwise not be screened, researchers said.
“Ideally, we want as many people as possible to get screened for colorectal cancer, and that’s likely going to mean a combination of different tests being used across the population,” Ladabaum said.
However, the blood test is still so new that it isn’t covered by existing colon cancer screening guidelines, and it’s not clear how many people will choose it, researchers noted.
“It remains to be seen who will really use the blood tests,” Ladabaum said. “Will it be people who have never been screened using any other method? And will they be willing to get a follow-up colonoscopy if indicated?”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-30 00:00
Read more
- New Alzheimer's prevention trial receives $74.5 million NIH grant
- ED Visit Rate 36.1 per 1,000 Older Adults With Alzheimer Disease
- Generic Medications Can Keep OOP Costs Down for Neurological Conditions
- Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina
- UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024
- Election Fears Are Compromising the Sleep Health of Americans
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions